| ¿µ¹® | urinary system | ÇÑ±Û | ºñ´¢±â°èÅë |
|---|---|---|---|
| ¼³¸í | ºñ´¢±â°èÅëÀ̶óÇϸé ÄáÆÏÀ¸·ÎºÎÅÍ ½ÃÀÛÇØ¼ ¿ä°ü, ¹æ±¤, ¿äµµ¿¡ À̸£´Â ÀÏ·ÃÀÇ ¿ÀÁÜ»ý¼º ¹× ÀúÀå, ¹è¼³±â°üÀ» ÀÏÄ´´Ù. ÄáÆÏÀº ±æÀÌ ¾à 2.5cm, Æø ¾à 5.1cm, µÎ²² ¾à 2.5cm, ¹«°Ô ¾à 120~160gmÀ¸·Î¼, ³»Ãø¿¡ ÄáÆÏ¹®ÀÌ ÀÖ¾î Ç÷°ü, ½Å°æ, ¿ä°üÀÌ ÃâÀÔÇϰí ÀÖ´Ù. ÄáÆÏÀº ¼ÓÁú°ú °ÑÁú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¼öÁúÀº 10~15°³ÀÇ Ãßü(¿ÀÁÜÀ» ¸ðÀ¸´Â ¿ªÇÒ)¸¦ Çü¼ºÇÏ°í °ÑÁúÀº ¾à 100¸¸°³ÀÇ ÄáÆÏ´ÜÀ§À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¿ä¼¼°üÀº Å丮ÂÊ´¢¼¼°ü, Çî·¹°í¸®, ¸ÕÂÊ´¢¼¼°ü, ÁýÇÕ°üÀ¸·Î Çü¼ºµÇ¾î ÀÖÀ¸¸ç, Ãßü¿Í ¼úÀÜ, ±ò¶§±â¸¦ °ÅÃÄ ¿ä°üÀ¸·Î ¿¬°áµÈ´Ù. ÄáÆÏÀº Ç÷¾×À» ¿©°úÇÏ¿© ½Åü ½ÅÁø´ë»çÀÇ ÃÖÁ¾»ê¹°À» ¿ÀÁÜÀÇ ÇüÅ·Π¹è¼³Çϸç, ¼¼Æ÷¿Ü¾×(extracellular fluid)ÀÇ ÀüÇØÁú³óµµ¸¦ Á¶ÀýÇÑ´Ù. ÄáÆÏ¿¡¼ Çü¼ºµÈ ¿ÀÁÜ´Â ¿ä°üÀ» °ÅÃÄ ¹æ±¤¿¡¼ ÀúÀåµÇ°í ÀÖ´Ù°¡ Àû´çÇÑ ½Ã±â°¡ µÇ¸é ¿äµµ¸¦ ÅëÇØ ¿Ü°è·Î ¹èÃâµÈ´Ù. |
||
| ¿µ¹® | urinary tract | ÇÑ±Û | ¿ä·Î |
|---|---|---|---|
| ¼³¸í | ¿ÀÁÜÀ» ¸ö ¹ÛÀ¸·Î ¹èÃâÇϱâ À§ÇÑ ±æ. ÄáÆÏ, ¿ä°ü, ¹æ±¤, ¿äµµ·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. |
||
| ¿µ¹® | urinary incontinence | ÇÑ±Û | ¿ä½Ç±Ý |
|---|---|---|---|
| ¼³¸í | ¹æ±¤Á¶ÀÓ±Ù ¹× ¿äµµÁ¶ÀÓ±ÙÀÇ ¼öÀÇÀû Á¶ÀýÀÌ ¾ÈµÇ±â ¶§¹®¿¡ ¿ÀÁÜÀÌ Ç×»ó, ¶Ç´Â ¶§¶§·Î ºÒ¼öÀÇÀûÀ¸·Î ¹è¼³µÇ´Â °Í. Âü½Ç±Ý(true incontinence): ½Å°æ°èÅëÀÇ ÀÌ»ó¿¡ ÀÇÇÑ Áø¼º¿ä½Ç±Ý. ½Å°æ°èÅëÀÇ ÀÌ»óÀ̹ǷΠġ·á´Â ºÒ°¡´ÉÇÑ °æ¿ì°¡ ¸¹´Ù. ±ä¹Ú½Ç±Ý(urge incontinence): ¹æ±¤ µîÀÇ ¿°Áõ¿¡ ÀÇÇÑ ±Þ¹Ú¿ä½Ç±Ý. ¿°Áõ¿¡ ÀÇÇÑ ÀÚ±ØÁõ»óÀ¸·Î ¿°ÁõÀ» Ä¡·áÇϸé ÀÚ¿¬È÷ ¼Ò½ÇµÈ´Ù. ½ºÆ®·¹½º½Ç±Ý(stress incontinence): °ñ¹ÝÀÇ ÇØºÎÇÐÀû ÁöÁö±¸Á¶ÀÇ ¾àÈ¿¡ ÀÇÇØ ±âħ µî º¹¾ÐÀÌ Áõ°¡ÇÏ´Â »óȲ¿¡¼ ¼ø°£ÀûÀ¸·Î ¹ß»ýÇÏ´Â ¿ä½Ç±Ý. ´ë°³ ³ªÀÌ ¸¹Àº ¿©¼º¿¡¼ ¸¹À¸¸ç, ´ÙÃâ»êÀÇ °æ·ÂÀ» °¡Áö°í ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû ¹æ¹ýÀÌ´Ù. ³Ñħ½Ç±Ý(overflow incontinence): ¹æ±¤ÀÌÇϺÎÀ§ÀÇ Æó»ö¿¡ ÀÇÇØ ¿ÀÁÜÀÌ ¹è¼³µÇÁö ¸øÇÏ°í ¹æ±¤¿¡ Àú·ùµÇ´Ù°¡ ¹æ±¤ÀÇ ÀúÀå¿ë·®À» ³Ñ´Â ¼ø°£ ÁÖüÇÏÁö ¸øÇÏ°í ³ªÅ¸³ª´Â ¿ä½Ç±Ý. |
||
| BPV | benign paroxysmal vertigo; benign positional vertigo; bioprosthetic valve; bovine papilloma virus |
|---|---|
| UAP | unlicensed assistive personnel; unstable angina pectoris; urinary acid phosphatase; urinary alkaline... |
| UCP | uncoupling protein; urinary coproporphyrin; urinary C-peptide |
| UTI | urinary tract infection; urinary trypsin inhibitor |
| FMN | first malignant neoplasm; flavin mononucleotide; frontomaxillonasal [suture] |
| lymph nodes of abdominal organs | The numerous lymph nodes receiving lymph from abdominal organs located in association with the visceral branches of the aorta. Synonym: nodi lymphatici abdominis viscerales. (05 Mar 2000) |
|---|---|
| antibodies, neoplasm | Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens. (12 Dec 1998) |
| antigens, neoplasm | Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. (12 Dec 1998) |
| brain neoplasm | Neoplasms of the part of the central nervous system contained within the cranium. (12 Dec 1998) |
| genes, structural, neoplasm | DNA sequences that code for RNA and for the proteins required for the enzymatic and structural function of neoplastic cells. (12 Dec 1998) |
| mucinous cystic neoplasm of pancreas | <radiology> = macrocystic adenoma of pancreas, cystadenoma / cystadenocarcinoma, M:F = 1:9, 40-60 years of age, malignant or pre-malignant, large mass (mean 12 cm), multilocular cysts, thick septations, tail / body in 85% (unlike adenocarcinoma and microcystic adenoma), hypo-/avascular, Differential diagnosis: panc pseudocyst, ** Cf: microcystic adenoma (12 Dec 1998) |
| histoid neoplasm | Old term for a neoplasm characterised by a cytohistologic pattern that closely resembles the tissue from which the neoplastic cells are derived. (05 Mar 2000) |
| neoplasm | <oncology, pathology> New and abnormal growth of tissue, which may be benign or cancerous. (16 Dec 1997) |
| neoplasm circulating cells | Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumours. (12 Dec 1998) |
| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
| neoplasm invasiveness | Ability of neoplasms to infiltrate and actively destroy surrounding tissue. (12 Dec 1998) |
| neoplasm metastasis | The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. The ability to metastasize is characteristic of all malignant neoplasms. (12 Dec 1998) |
| neoplasm recurrence, local | The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. (12 Dec 1998) |
| neoplasm regression, spontaneous | Disappearance of a neoplasm or neoplastic state without the intervention of therapy. (12 Dec 1998) |
| neoplasm, residual | Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication) (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|